[Pre-operation application of recombinant human growth hormone for liver cirrhosis with portal hypertension and hypoproteinemia].

What Was Tested

Researchers studied Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in this randomized controlled trial publication.

Who Took Part

PubMed indexes the participants as adults and middle-aged adults, both men and women.

Sixty patients with liver cirrhosis and portal hypertension and hypoproteinemia (child's class B) were randomly divided into control group (n = 30) and rhGH group (n = 30).

All patients were given the same parenteral nutrition before operation.

How the Study Was Run

In design terms this was a randomized study.

The participants were allocated by chance, so the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) group and the comparison group should start out alike.

The levels of albumin, globulin, prealbumin, and blood sugar were measured before and 3, 4, and 5 days after given the hormone.

No side effects had been found.

The blood sugar and globulin did not change over time in both groups.

What Was Measured

Topics PubMed links to this paper include Human Growth Hormone, Hypertension, Portal, Hypoproteinemia, Liver Cirrhosis, Parenteral Nutrition, Total, Preoperative Care and Recombinant Proteins.

What This Means in Plain Language

The paper is a randomized study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

Results are reported in around 1 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2003 (Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition), a journal based in China.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.